When we included these factors in a multivariate Cox regression analysis, concomitant oncogene mutations (HR 2.615 [95% CI 1.398–4.889]; P = 0.0026) and tumor-suppressor gene mutations (HR 2.122 [95% CI 1.264–3.564]; P = 0.0044) both remained independent negative factors affecting the efficacy of crizotinib for patients with ALK rearrangement NSCLC (Figure 3B). The gene discussed is ALK; the disease is non-small cell lung carcinoma.